15 Recruiting Studies Using Crizotinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Crizotinib
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
View Study & Checklist ➔A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
📍 Local Institution - 0221 — Des Moines, Iowa
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
📍 Florida Cancer Specialists — Altamonte Springs, Florida
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
ALK Gene Rearrangement
View Study & Checklist ➔IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
📍 Honor Health — Scottsdale, Arizona
Metastatic Uveal Melanoma
View Study & Checklist ➔Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
📍 Moffitt Cancer Center — Tampa, Florida
Non-small Cell Lung Cancer
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
📍 Oncocentro Serviços Médicos e Hospitalares Ltda — Fortaleza, Ceará
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
📍 UCLA Medical Center — Los Angeles, California
Metastatic Uveal Melanoma
View Study & Checklist ➔Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
📍 Cross Cancer Institute — Edmonton, Alberta
Lymphoma, Non-Hodgkin
View Study & Checklist ➔